# Peptide lab results and clinical outcomes

> Lab reports | Peptide Clinical Evidence Journal — Peptide Clinical Evidence Journal compares MOTS-c, semaglutide, retatrutide and tesamorelin by their lab changes, clinical outcomes and safety questions.

A result becomes more interesting when the neighboring entries stop agreeing with it.

## Results beside their complications

A metabolic winner would be a convenient answer. I see incompatible clinical questions across these studies. The clinically relevant question changes from one row to the next, and so does the reason for caution.

| Compound | Observation | Accompanying question |
|---|---|---|
| [MOTS-c](/mots-c) | [Higher blood levels accompanied greater death or cardiovascular-event risk in dialysis](https://pubmed.ncbi.nlm.nih.gov/39111290/) | The cohort measured endogenous peptide. What would a human treatment trial find? |
| [Semaglutide](/semaglutide) | [Cardiovascular events fell in SELECT](https://pubmed.ncbi.nlm.nih.gov/37952131/) and [major kidney outcomes fell in FLOW](https://pubmed.ncbi.nlm.nih.gov/38785209/) | The [safety review raises the eye concern with rapid glucose correction](https://pubmed.ncbi.nlm.nih.gov/34305810/) in people with existing diabetic retinopathy. |
| [Retatrutide](/retatrutide) | [Triglyceride and insulin-resistance markers improved](https://doi.org/10.1210/clinem/dgag201) | The [obesity trial also recorded a dose-related resting-heart-rate increase](https://pubmed.ncbi.nlm.nih.gov/37366315/). Longer-term significance remains open. |
| [Tesamorelin](/tesamorelin) | [Visceral and liver fat fell in HIV-associated lipodystrophy trials](https://pubmed.ncbi.nlm.nih.gov/41545261/) | [Growth hormone and IGF-1 rise](https://pubmed.ncbi.nlm.nih.gov/20943777/); long-term hormonal safety remains a separate question. |

The entries concern different populations and research designs. The MOTS-c row is observational; the other rows include human treatment trials. Their placement together is an invitation to inspect the differences.

## Where events were counted

The [SELECT cardiovascular result](https://pubmed.ncbi.nlm.nih.gov/37952131/) came from adults with established cardiovascular disease and overweight or obesity, without diabetes. The [FLOW kidney result](https://pubmed.ncbi.nlm.nih.gov/38785209/) came from adults with type 2 diabetes and chronic kidney disease. Their combined endpoints included serious illness and death, with different definitions.

That gives semaglutide the firmest direct serious-illness evidence among these four compounds in this journal. It leaves room for digestive harms, gallbladder disease and specific safety concerns. A strong efficacy finding can coexist with an important safety qualification.

Retatrutide’s [weight and liver-fat trials](https://pmc.ncbi.nlm.nih.gov/articles/PMC11271400/) and tesamorelin’s [body-composition trials](https://pubmed.ncbi.nlm.nih.gov/41545261/) measured valuable changes without resolving comparable long-term outcome questions. MOTS-c’s [mouse performance findings](https://pubmed.ncbi.nlm.nih.gov/33473109/) remain experiments in mice. I distrust the favorable measurement drafted to answer a different clinical question.

## Approved uses and individual decisions

Semaglutide is an approved prescription medicine for particular uses. [Tesamorelin’s approved use](https://www.ncbi.nlm.nih.gov/books/NBK548730/) concerns excess abdominal fat in adults with HIV-associated lipodystrophy. [Retatrutide remains investigational](https://pmc.ncbi.nlm.nih.gov/articles/PMC12190491/), and MOTS-c has no FDA-approved human use in these sources.

Those distinctions affect the clinical setting in which evidence can be applied. Personal care also depends on existing illnesses, medicines and an individual assessment. A collection of papers cannot provide that assessment. The [reading list](/references) provides the underlying studies for a closer look.

---

Peptide Clinical Evidence Journal independently examines where metabolic biomarkers align with clinical outcomes; it is neither a clinic nor a vendor and does not provide medical advice.